StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals
ERASBullishEarningsnews
High materiality8/10

ERAS-0015 data boosts ERAS pipeline toward registration-readout catalysts 2027

Aug 11, 2026, 4:09 PM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

Strong early data for ERAS-0015 and a robust financing runway improve near-term visibility and potential for milestone-driven upside; however, outcomes remain early-stage and data-dependent.

AI summary

What happened, with direct paths to the underlying reporting

ERAS-0015 updated U.S. trial data show 57% uORR<8wk in 2L+ KRAS G12X PDAC with favorable tolerability, and initial doses combined with panitumumab show no DLTs. Erasca also outlined three potentially registration-enabling trials for 2027 and expects ERAS-4001 data in H2 2026, supported by a $632.5 million upsized financing that strengthens the balance sheet for pipeline catalysts.

  • ERAS-0015 shows 57% uORR<8wk in 2L+ KRAS G12X PDAC; tolerability solid.
  • 16–32 mg panitumumab combos show no DLTs; cohort escalation ongoing.
  • Upsized financing: ~$632.5M gross; strengthens balance sheet.
  • Three registration-enabling ERAS-0015 trials planned for 2027; H1 2027 readouts.
  • ERAS-4001 data due H2 2026; Phase 1 monotherapy data in 2026–2027.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Related signals

More source-backed signals connected by company or event